P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models

Molecular Cancer Therapeutics

Volumn 6, Issue 3, 2007, Pages 926-934

  Joshi, Kalpana S ^a   Rathos, Maggie J ^a   Mahajan, Pravin ^a   Wagh, Vilas ^a   Shenoy, Satyendra ^a   Bhatia, Dimple ^a   Chile, Shailaja ^a   Sivakumar, Meenakshi ^a   Maier, Armin ^b   Fiebig, Heinz Herbert ^b   Sharma, Somesh ^a  

^a Piramal Enterprises Limited   (India)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; P 276 00; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL POPULATION; CELL STRAIN HL 60; CELL SYNCHRONIZATION; CLONOGENIC ASSAY; COLON CARCINOMA; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG POTENCY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CANCER; LEWIS CARCINOMA; LUNG FIBROBLAST; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; CISPLATIN; CYCLIN-DEPENDENT KINASES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FLAVONES; FLOW CYTOMETRY; G2 PHASE; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34147167723     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0614     Document Type: Article

References (25)

1. Morgan DO. Cell cycle control in normal and neoplastic cells. Curr Opin Genet Dev 1992;2:33-7.
2. Malumbres M, Barbacid M. To cycle or not to cycle: a decision in cancer. Nat Rev Cancer 2001;1:222-31.
3. Obaya AJ, Sedivy JM. Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci 2002;59:126-42.
4. Pines J. The cell cycle kinases. Semin Cancer Biol 1994;5:305-13.
5. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
6. Ekholm SV, Reed SI. Regulation of G (1) cyclin dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000;12:676-84.
7. Ho A, Dowdy SF. Regulation of G (1) cell cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev 2002;12: 47-52.
8. 1. Cell 1999;98: 859-69.
9. 1 phase of the cell cycle. Cell 1991;65L:701-13.
10. Harbour JW, Dean DC. The Rb/E2F pathway: expending roles and emerging paradigms. Genes Dev 2000;14:2393-409.
11. Nevins JR. The Rb/E2F pathway and cancer. Human Mol Genet 2001;10:699-703.
12. Sellers WR, Kaelin WG. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1977;15:3301-12.
13. Hall M, Peters G. genetic alterations of cyclins, cyclin dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68: 67-108.
14. 1-S-regulating genes in human cancer. Prog Cell Cycle Res 1997;3:211-20.
15. Roth T, Burger AM, Dengler WA, Willmann H, Feibig HH. Human tumor cell lines demonstrating the characteristics of patient tumors as useful models for anticancer drug screening. In: Fiebig HH, Burger AM editors. Relevance of tumor models for anticancer drug development. Contributions Oncology, vol. 54. Basel: Karger; 1999; pp. 145-56.
16. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumor xenografts: correlation of in vitro to in vivo activity as basis for anticancer drug discovery. Eur J Cancer 2004;40:802-20.
17. Dengler WA, Schulte J, Berger DP, Mertelsmann R, Fiebig HH. Development of a propidium fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs 1995;6:522-32.
18. Scholz CC, Berger DP, Winterhalter BR, Hen BH, Fiebig HH. Correlation of drug response in patients and in the clonogenic assay with solid human tumor xenografts. Eur J Cancer 1990;26:901-5.
19. Von Hoff DD. Human tumor cloning assays: application in clinical oncology and new antineoplastic agent development. Cancer Met Rev 1988;7:357-71.
20. Alley MC, Uhi CB, Leiber MM. Improved detection of drug cytotoxicity in the soft agar colony forming assay through use of a metabolizable tetrazolium salt. Life Sci 1982;31:3071-8.
21. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes, and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-9.
22. Eastman A. The formation, isolation, and characterization of DNA adducts produced anticancer platinum complexes. Pharmacol Ther 1987; 34:155.
23. 2/M checkpoint. Genes Dev 2000;14:1584.
24. Fiebig HH, Berger DP, Dengler WA, Wallbrecker E, Winterhalter BR. Combined in vitro/in vivo test procedure with human tumor xenografts. In: Fiebig HH, Berger DP, editors. Immunodeficient mice in oncology. Contributions Oncology, vol. 42. Basel: Karger 1992; pp. 321-51.
25. Shapiro GI. Cyclin-dependent pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.